Hereditary Angioedema Management: From Dealing to Leading

Abstract

A two-part digital symposium series entitled ‘Hereditary Angioedema (HAE) Management: From Dealing to Leading,’ took place during the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress, held in Prague, Czechia, in July 2022. The first symposium, ‘The Journey Towards Disease Control in HAE’, held on 1st July 2022, was chaired by Markus Magerl, Department of Dermatology and Allergy, Charite Universitätsmedizin, Berlin, Germany. Speakers Grzegorz Porębski, Department of Clinical and Environmental Allergology, Jagiellonian University Medical College, Kraków, Poland, and Mauro Cancian, Department of Systems Medicine, University of Padova, Italy, discussed how the advent of new disease-specific HAE treatments have contributed to the evolution of the HAE management guidelines, and the resulting impact on the lives of patients with HAE. The latest international management guidelines from the World Allergy Organization (WAO)/EAACI newly define the goals of treatment in HAE as achieving total control of the disease and normalising patients’ lives, stressing that this can currently only be achieved by long-term prophylactic (LTP) treatment. The second symposium, ‘Making the Goals of HAE Management Achievable with Subcutaneous C1-Inhibitor’, held on 2­nd July 2022, was chaired by Pavlína Králíčková, Department of Clinical Immunology and Allergology, University Hospital Hradec Králové, Czechia, who also provided a brief overview of the development of the subcutaneous formulation of C1-inhibitor for LTP. Emel Aygören-Pürsün, Angioedema Clinic and Center for Hereditary Angioedema, University Hospital Frankfurt, Goethe University, Germany, and Teresa Caballero, Allergy Department, Hospital Universitario La Paz, Madrid, Spain, then used case studies to highlight the necessity of assessing and monitoring a patient’s disease activity, the associated quality of life, and disease control to allow for possible adaptations to the treatment plan. Both speakers also highlighted how the use of subcutaneous C1-inhibitor for LTP can contribute towards the achievement of the goals of HAE treatment, namely achieving total disease control and normalising patients’ lives.